CLDX — Celldex Therapeutics, Inc.

Is CLDX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Celldex Therapeutics, Inc. (CLDX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $28.04. The rating moved from Neutral to Strong Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Celldex Therapeutics is a small-cap biotech whose near-term performance will be driven primarily by binary clinical and corporate catalysts and by its ability to fund operations without excessive dilution. Market conditions are currently calm, which may compress volatility and delay decisive moves absent new data. Sector-level consolidation and distributor shifts create potential strategic upside (partnerships or M&A), but that is balanced against typical biotech risks: trial setbacks, regulatory/reimbursement hurdles, competitive pressure and financing needs. Monitor upcoming clinical milestones, cash runway disclosures, and any partnership or licensing activity to reassess outlook.

Key factors

  • Small-cap biotech with an early- to mid-stage clinical pipeline that creates binary, high-volatility catalysts (clinical readouts, regulatory milestones).
  • Limited recent public financial detail available in the provided dataset increases emphasis on cash runway and potential near-term financing as drivers of share movement.
  • Sector themes: consolidation by large-cap pharma and distributor shifts toward specialty care could create M&A interest or partnership opportunities for specialty franchises.
  • Current overall market tone is measured risk-on with low intraday volatility, which may mute short-term breakout moves for speculative names.
  • Defensive flows into large-cap pharma reduce breadth of capital available to small biotechs, pressuring relative performance despite idiosyncratic upside from positive clinical news.

Risks

  • Clinical trial failures or negative interim readouts that would materially reduce valuation and investor appetite.
  • Need for dilutive financing if cash runway is insufficient, leading to share issuance and equity dilution.
  • Regulatory and reimbursement uncertainty that can limit commercial prospects even if clinical efficacy is demonstrated.
  • Competitive risk from larger, better-funded pharma and biotech players developing overlapping therapies.
  • Low liquidity and high share-price volatility typical of smaller biotech names, increasing execution risk for investors.
  • Sector/regulatory shifts (e.g., Medicare/Medicaid program integrity actions) that could indirectly affect commercial dynamics or payer behavior.

See today's live rating, score and targets

Members see the live hourly rating for CLDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.